P11.04 * MALT CNS LYMPHOMAS: A MONOCENTRIC EXPERIENCE
نویسندگان
چکیده
منابع مشابه
Non-MALT marginal zone lymphomas.
The concept of marginal zone B-cell lymphomas was developed in the 1990s for lymphomas whose cells originate from B lymphocytes normally present in a distinct anatomical location, the so-called ‘marginal zone’ (MZ). MZ has been described in the lymphoid organs—spleen and lymph nodes—and in nonlymphoid organs—mucosa-associated lymphoid tissue (MALT) or non-mucosal tissue such as skin, orbit and ...
متن کاملThe management of nongastric MALT lymphomas.
The group of marginal zone B-cell lymphomas (MZL) comprises three different entities, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (currently called MALT lymphoma), nodal marginal zone B-cell lymphoma (previously known as monocytoid lymphoma), and splenic marginal zone B-cell lymphoma (with or without circulating villous lymphocytes).[1-3] Primary splenic and no...
متن کاملHow I treat CNS lymphomas.
The pathogenesis of primary and secondary central nervous system (CNS) lymphoma poses a unique set of diagnostic, prognostic, and therapeutic challenges. During the past 10 years, there has been significant progress in the elucidation of the molecular properties of CNS lymphomas and their microenvironment, as well as evolution in the development of novel treatment strategies. Although a CNS lym...
متن کاملMarginal zone lymphomas: management of nodal, splenic, and MALT NHL.
Marginal zone lymphomas are indolent B-cell lymphomas that originate from the marginal zone of B-cell follicles. For several subtypes, the initiation of disease appears to be a consequence of chronic infection and/ or inflammation. While the initial lymphoid hyperplasia is driven by physiologic antigenic stimulation, additional oncogenic events, such as chromosomal translocations leading to con...
متن کاملDabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2014
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/nou174.227